Home » Topics » Regulatory » EMA

EMA
RSS

EMA committee recommends approval of Xolair in new indication

Jan. 24, 2014

Novartis to request re-examination of E.U. filing for serelaxin

Jan. 24, 2014

Cytonet files MAA with EMA for use of liver cell therapy to treat urea cycle disorders in children

Jan. 17, 2014

EMA committee recommends suspending use of Protelos/Osseor

Jan. 15, 2014

EMA accepts Biovest's MAA for BiovaxID

Jan. 14, 2014

Fenfluramine obtains orphan drug designation in the U.S. and E.U. for Dravet syndrome

Jan. 10, 2014

EMA grants accelerated review to Bristol-Myers' MAA for daclatasvir in chronic HCV

Jan. 10, 2014

Cytovir ADV ready to receive orphan drug designation in Europe

Jan. 8, 2014

CHMP gives positive opinion on subcutaneous tocilizumab

Dec. 27, 2013

EMA accepts tolvaptan MAA for ADPKD

Dec. 27, 2013

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 6, 2026.
CROI 2026: Neurodegeneration, the challenge of aging with HIV
BioWorld
Antiretroviral therapies against HIV have been in use for more than 30 years and have enabled people living with HIV to maintain undetectable viral levels. Many...
CROI 2026 highlights depression and cognitive vulnerability in HIV
BioWorld
The effects of aging pose an additional challenge for people with HIV due to the neurological and psychological consequences that persist despite antiretroviral...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 3, 2026
Slate Medicines launches with focus on headache disorders
BioWorld Science
Slate Medicines Inc. has launched with $130 million in series A financing and a focus on advancing next-generation therapeutics for migraine and other headache...